Transformation of Portfolio, Reduced Valuation, and Cyclical Recovery Anticipated to Boost Upside for Hillenbrand

Hillenbrand Inc., a leading industrial company, has reported its Q3 2025 results, showing a 24% year-over-year decline in revenue to $599 million, although a 10% decline on a pro forma basis. This decrease can be attributed to various factors, including lower volumes and an unfavourable product mix.

Despite the revenue drop, Hillenbrand's Food, Health & Nutrition (FHN) segment has seen significant growth, accounting for over a quarter of the company's total revenue – an increase from a mere 3% in 2022.

The Molding Technology Solutions (MTS) segment experienced a 58% year-over-year decline, primarily due to the MIME business divestiture. However, the MTS segment's backlog saw a 7% increase on a pro forma basis, driven by stronger demand for hot runners and controllers.

Advanced Process Solutions (APS), on the other hand, reported an 11% decline in revenue, mainly due to lower capital equipment demand. APS's adjusted EBITDA margin fell 340 bps to 15.8%, and MTS's margin declined 170 bps on a pro forma basis to 19.9%.

Pro forma net leverage now sits at 3.7x after the TerraSource sale in early Q4, above the target range of 1.7x to 2.7x. This high leverage has led management to pause M&A activities until the leverage comes back in line.

Hillenbrand's stock trades at a discount to its five-year average forward P/E of about 12.0x, offering potential value for investors. The company's 3.5% dividend yield adds another layer of support.

Recent acquisitions by Hillenbrand, such as SP Scientific, Advant Medical, and Osgood Industries, have strengthened the company's presence in the medical technology, pharmaceutical, and industrial markets. Hillenbrand has also captured $40 million in cross-selling synergies from the Linxis, FPM, and Coperion acquisitions.

However, the company's return to revenue growth may be delayed if macroeconomic conditions worsen or the improvement in quoting activity fades. There is also a risk of adverse impact on growth if Hillenbrand fails to realize cost synergies from future acquisitions.

Despite these challenges, Hillenbrand remains optimistic about its future prospects and is committed to driving growth and shareholder value. The company will continue to focus on executing its strategic initiatives, leveraging its strong portfolio of brands, and capitalising on growth opportunities in its core markets.

Transformation of Portfolio, Reduced Valuation, and Cyclical Recovery Anticipated to Boost Upside for Hillenbrand